Roman Fleck
Chief Executive Officer
Business and Management
Janpix
Canada
Biography
Roman is the CEO of Janpix, Ltd., as well as a Venture Advisor to Medicxi (formerly Index Ventures Life Sciences). Previously, he was a Principal at Index Ventures where among others he invested in and represented Index Ventures on the boards of GlycoVaxyn (sold to GSK), Versartis (NASDQ: VSAS), and Novocure (NASDQ: NVCR). Earlier at Index Ventures he was also involved with Funxional Therapeutics (sold to Boehringer Ingelheim) and Micromet (sold to Amgen). He started his career at Boehringer Ingelheim Pharmaceuticals in Connecticut where he led drug development projects in oncology, inflammation and cardiovascular disease, advancing several compounds from pre-clinical to clinical stage. Roman received a PhD in bioorganic chemistry from MIT as well as an MBA from NYU’s Stern School of Business. He has authored or co-authored numerous publications in prestigious journals as well as many issued patents. Roman is the CEO of Janpix, Ltd., as well as a Venture Advisor to Medicxi (formerly Index Ventures Life Sciences). Previously, he was a Principal at Index Ventures where among others he invested in and represented Index Ventures on the boards of GlycoVaxyn (sold to GSK), Versartis (NASDQ: VSAS), and Novocure (NASDQ: NVCR). Earlier at Index Ventures he was also involved with Funxional Therapeutics (sold to Boehringer Ingelheim) and Micromet (sold to Amgen). He started his career at Boehringer Ingelheim Pharmaceuticals in Connecticut where he led drug development projects in oncology, inflammation and cardiovascular disease, advancing several compounds from pre-clinical to clinical stage. Roman received a PhD in bioorganic chemistry from MIT as well as an MBA from NYU’s Stern School of Business. He has authored or co-authored numerous publications in prestigious journals as well as many issued patents.
Research Interest
Business and Management
